This hybrid virus demonstrated multi-modal efficacy against sarcomas, combining the robust replication and cytolytic activity of the VSV backbone with the distinct cell entry and immune-modulating properties conferred by the MORV glycoprotein. The gene discussed is ART4; the disease is sarcoma.